Redx to Present at the 2 nd Annual Wnt & Catenin Pathway Targeted Drug Development Summit

Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, announces that Dr. Simon Woodcock, Vice President, Oncology at Redx Pharma, will present at the 2 nd Annual Wnt & Catenin Pathway Targeted Drug Development Summit (24 - 26 January, Boston, MA).

In the presentation, which will take place on Thursday 26 January at 10:30 (EST), Dr. Woodcock will discuss the challenges of genetic selection in defined patient populations and how this relates directly to Wnt/Catenin Biomarkers in patient selection for clinical studies of targeted therapies, such as Redx's RXC004.

RXC004 is a clinical stage, highly potent and selective, orally active Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand dependent cancer. It is currently being evaluated in Phase 2 proof-of-concept clinical studies as a monotherapy and in combination with anti-PD-1, Nivolumab, in genetically selected metastatic colorectal cancer (MSS mCRC) (clinicaltrials.gov NCT04907539), as monotherapy in genetically selected pancreatic cancer, and as a monotherapy and in combination with anti-PD-1, Pembrolizumab, in biliary tract cancers (clinicaltrials.gov NCT04907851).

Contact:

Tel: +44 (0)1625 469 918

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, commenced a Phase 2 programme in November 2021. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA/IND application at the end of 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.